Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapsed/refractory FLT3-mutated acute myeloid leukemia: A Japanese nationwide registry study

View Full Paper
Ask AI
Bookmark
Share

Authors

TITakashi IshidaHUHiroki UchidaATAkiyoshi Takami

Discussion

Loading...

Member takes

Overview

Nationwide registry study demonstrates gilteritinib maintenance reduces relapse incidence in FLT3-mutated AML patients post-transplant, highlighting its safety profile and efficacy.

Key Points

  • This study aimed to evaluate the effectiveness and safety of gilteritinib as maintenance therapy following transplant in FLT3-mutated AML patients.
  • Analyzed data from the Japanese national transplant registry and a secondary survey for mutation status.
  • Included relapsed/refractory FLT3-mutated AML patients who received gilteritinib before and/or after transplant.
  • Evaluated gilteritinib dosing, safety, and outcomes including relapse-free survival and overall survival.
  • Post-HSCT gilteritinib maintenance showed improved relapse-free survival (RFS): 58.8% vs. 36.4%.
  • Majority experienced adverse events necessitating dose adjustments: infections (25.5%), cytopenias (21.8%), liver dysfunction (16.4%).
  • The 3-year overall survival was higher in the maintenance group: 64.4% vs. 41.4%, particularly in cord blood transplant recipients.

Cite This Study

Ishida et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e22chttps://doi.org/10.1182/blood-2025-4289
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapse/refractory FLT3-mutated acute myeloid leukemia2026 · 3 citations
  2. 2Gilteritinib maintenance therapy after allogeneic hematopoietic stem cell transplantation in FLT3-mutated AML: A systematic review and meta-analysis2025
  3. 3Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations2026
  4. 4Post‐stem cell transplant maintenance in FLT3<sup>mut</sup> acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib2024 · 4 citations
  5. 5Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS‐like tyrosine kinase 3 ( <scp>FLT3</scp> )‐mutated acute myeloid leukaemia patients: A multicentre real‐world study2026